Personalized Medicine Biomarkers Market Size to Reach USD 77.37 Billion by 2034

The global personalized medicine biomarkers market was valued at USD 24.88 billion in 2025. The market is projected to reach USD 77.37 billion by 2034, registering a CAGR of 13.4% from 2026 to 2034. Biomarkers are now being used to give physicians more information about individual patients. Their use is particularly established in treatment decisions for diseases with known molecular markers. Research is also moving into earlier detection and patient monitoring.

Biomarker Testing Moves Beyond a Single Clinical Use

A biomarker test does not serve the same purpose in every case. Some tests are used before treatment to help determine which therapy fits a patient. Others are used to follow changes in a disease after treatment has started.

The distinction is becoming important as more medicines are developed around specific biological targets. A test can identify the marker needed for a particular therapy. This approach has become well established in cancer care.

Biomarker research is not limited to cancer. Diabetes is another area where researchers are looking for markers that can provide more information about disease development and complications. Similar work is underway in neurology, autoimmune diseases, and cardiology.

Genomic Testing Remains an Important Part of the Market

The technology used to find biomarkers varies with the marker being examined. Comprehensive genomic profiling can look at several genetic changes in one test. PCR assays are more targeted and can be used when a known mutation needs to be checked.

Proteins can be detected using techniques like immunohistochemistry. The emerging discipline of proteomics is also contributing to research on proteins that are altered due to certain conditions.

Liquid biopsy provides yet another alternative for molecular analysis. Liquid biopsy involves sampling of blood in order to analyze tumor-related genetics. The technique can be used when obtaining tissue biopsies would prove challenging. Circulating tumor cells and extracellular vesicles are being considered by researchers as possible sources of biomarkers.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: Personalized Medicine Biomarkers Market Report

Oncology Holds the Largest Indication Share

Oncology accounted for 35.7% of the personalized medicine biomarkers market in 2025. The large share reflects the number of biomarkers already used in cancer care.

Tumors can differ considerably at the molecular level, even when they occur in the same organ. Biomarker testing helps identify some of these differences. It is used to determine whether certain patients meet the biomarker criteria for a therapy.

Circulating biomarkers have also become an active area of research. CTCs and circulating cell-free DNA are being examined for their use in disease assessment. Molecular residual disease testing is another application under development.

The diabetes segment is projected to record the fastest growth in the personalized medicine biomarkers market. It is anticipated to account for a CAGR of 17.1% from 2026 to 2034. Research in this area is moving beyond conventional measures of disease control. Researchers are studying markers that may provide more detail on disease progression and patient differences.

FDA Activity Shows the Expanding Role of Companion Diagnostics

The FDA companion diagnostic records for 2026 include several new authorization actions tied to molecular biomarkers. These tests are used alongside specific therapies to identify patients who meet the relevant biomarker criteria.

Guardant360 CDx appeared in several of the 2026 actions. The tests covered biomarkers such as ESR1 and ERBB2/HER2 alterations. FoundationOne CDx also received new indications involving HRR alterations, KRAS and NRAS status, PIK3CA mutations, and MET exon 14 skipping.

The list also includes tests for BRAF, PTEN, RET, HER2, and PD-L1. This range shows how companion diagnostics are being used across different cancer types and treatment classes.

New Testing Approaches Expand the Scope of Biomarkers

Multi-biomarker panels are one area attracting research interest. Instead of ordering separate tests for individual markers, a panel can examine several markers from one sample. The approach may be useful when treatment decisions depend on more than one biological feature.

Biomarker discovery is also becoming more data-intensive. Researchers are working with large genomic and molecular datasets to identify signals associated with disease. AI-based analysis is being used in some research settings to screen these datasets and identify patterns for further study.

Hyper-personalized medicine takes this approach further. It focuses on using highly specific patient information when making medical decisions. Wider use of detailed molecular data could give this area greater relevance in future care.

North America Remains the Largest Regional Market

North America accounted for 51.3% of the personalized medicine biomarkers market in 2025. In addition, the U.S. has a broad system of diagnostic laboratories and companies involved in genome testing. State initiatives regarding insurance coverage for biomarker tests are relevant in this respect as well.

Asia Pacific is projected to grow at an 15.8% CAGR. Interest in genomics is increasing across Asia Pacific countries. In particular, China and Japan have developed their programs for genomic medicine. India is experiencing growing access to molecular diagnostics. Australia and South Korea have established research capacities as well.

Companies Compete Across Different Parts of the Biomarker Market

Competition in the personalized medicine biomarkers market is spread across several types of companies. Diagnostic manufacturers develop testing platforms and companion diagnostics. Laboratory companies provide testing services directly to healthcare providers. Pharmaceutical companies use biomarkers in drug development and patient selection.

The competitive focus also differs from one company to another. Some providers concentrate on genomic profiling. Others work in molecular diagnostics, proteomics, clinical laboratory testing, or genetic counseling.

Partnerships between pharmaceutical and diagnostic companies are common when a therapy depends on a particular biomarker. Regulatory clearance or approval can then become an important milestone for both sides.

Key companies include Abbott Laboratories; Alamar Biosciences, Inc.; AstraZeneca PLC; Becton, Dickinson and Company; F. Hoffmann-La Roche Ltd; Foundation Medicine, Inc.; Fujirebio Europe NV; Informed Medical Decisions, Inc.; Johnson & Johnson Innovative Medicine; Laboratory Corporation of America Holdings; Pfizer Inc.; QIAGEN N.V.; Quest Diagnostics Incorporated; and Thermo Fisher Scientific Inc.

Personalized Medicine Biomarkers Market Segmentation

By Indication Outlook (Revenue – USD Billion, 2021–2034)

• Oncology
  • By Type
    • Breast Cancer
    • Lung Cancer
    • Colon Cancer
    • Others
  • By Circulating Biomarkers
    • Circulating Tumor Cells(CTCs)
    • Circulating Cell-free DNA(cfDNA)
    • Extracellular Vesicles (EVs)
    • Other Circulating Biomarkers
• Neurology
• Diabetes
• Autoimmune Diseases
• Cardiology
• Others

By Application Outlook (Revenue – USD Billion, 2021–2034)

• Early Detection/Screening
• Diagnosis
• Treatment Selection
• Monitoring

By Regional Outlook (Revenue – USD Billion, 2021–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America